Pharmacokinetics of the carmustine implant

Clinical Pharmacokinetics

Volumn 41, Issue 6, 2002, Pages 403-419

  Fleming, Alison B ^a   Saltzman, W Mark ^a  

^a Cornell University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE;

ANIMAL EXPERIMENT; BRAIN TUMOR; COMPUTER SIMULATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG IMPLANT; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0036310748     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241060-00002     Document Type: Review

References (70)

1. Principles of treatment of malignant gliomas in adults: An overview
2. Do anticancer agents reach the tumor target in the human brain
3. High-dose chemotherapy for the treatment of malignant brain tumors
4. High-dose chemotherapy with autologous hematopoietic stem-cell rescue for patients with malignant brain tumors
5. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin
6. Osmotic opening of the blood-brain barrier: Principles, mechanism, and therapeutic applications
7. Osmotic blood-brain-barrier disruption and chemotherapy in the treatment of high-grade malignant glioma - Patient series and literature review
8. Glioma invasion in the central nervous system
9. The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma
10. Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas
11. The Ommaya reservoir in chemotherapy for malignant disease in the CNS
12. Implantable pumps for drug delivery to the brain
13. Polymers to treat brain tumors
14. Drug delivery to the brain using polymers
15. Polymers as controlled drug delivery devices for the treatment of malignant brain tumors
16. New delivery systems for brain-tumor therapy
17. Intratumoral chemotherapy
18. Drug delivery into the brain using implantable polymeric systems
19. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma
20. Biodegradable polymer implants to treat brain tumors
21. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent Gliomas
22. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent Gliomas
23. Alkylating agents
24. Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain
25. Brain biocompatibility of a biodegradable, controlled-release polymer in rats
26. Interstitial drug therapy for brain tumors - A case study
27. Interstitial chemotherapy of the 91-gliosarcoma - Controlled release polymers for drug delivery in the brain
28. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain
29. Interstitial chemotherapy of experimental brain tumors: Comparison of intratumoral injection versus polymeric controlled release
30. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors
31. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase 1 trial
32. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study
33. Morbidity and survival after 1,3-bis(2-chloroethyl)-1 nitrosourea wafer implantation for recurrent glioblastoma: A retrospective case matched cohort series
34. Polyanhydrides: 1. Preparation of high-molecular-weight polyanhydrides
35. Morphological characterization of polyanhydride biodegradable implant GLIADEL® during in vitro and in vivo erosion using scanning electron microscopy
36. Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors
37. Bioerodible polyanhydrides as drug-carrier matrices: 1. Characterization, degradation, and release characteristics
38. Bioerodible polyanhydrides as drug-carrier matrices: 2. Biocompatibility and chemical reactivity
39. Biomaterials in drug delivery and tissue engineering: One laboratory's experience
40. The antitumor agent, 1,3bis(2-chloroethyl)-1-nitrosourea
41. Effects of GLIADEL® wafer initial molecular weight on the erosion of wafer and release of BCNU
42. In-vivo versus in-vitro degradation of controlled-release polymers for intracranial surgical therapy
43. The development of polyanhydrides for drug delivery applications
44. Polymeric delivery systems for controlled drug release
45. Metabolic disposition and elimination studies of a radiolabeled biodegradable polymeric implant in the rat brain
46. Excretion of a radiolabeled anticancer biodegradable polymeric implant from the rabbit brain
47. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers
48. Transport of material between brain extracellular fluid, brain cells and blood
49. The movements of water and solutes in the brains of mammals
50. Drug 'diffusion' within the brain
51. Transport of cisplatin in rat brain following microinfusion: An analysis
52. Interaction between diffusion and Michaelis-Menten uptake of dopamine after ionophoresis in striatum
53. Transport of molecules in the tumor interstitium: A review
54. Drugs released from polymers: Diffusion and elimination in brain-tissue
55. Dextran retention in the rat brain following release from a polymer implant
56. Distribution of drugs following controlled delivery to the brain interstitium
57. Delivery and distribution of recombinant human nerve growth factor in the brain interstitium
58. Distribution of nerve growth-factor following direct delivery to brain interstitium
59. Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders
60. Transport and elimination of recombinant human NGF during long-term delivery to the brain
61. Chemotherapeutic drugs released from polymers: Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain
62. Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants
63. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain
64. Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema
65. A finite element model for predicting the distribution of drugs delivered intracranially to the brain
66. Intracranial drug delivery systems
67. The delivery of BCNU to brain tumors
68. Vascular and interstitial barriers to delivery of therapeutic agents in tumors
69. Magnetic resonance imaging appearance of carmustine-impregnated implantable wafers
70. Influence of schedule on alkylating agent cyto-toxicity in vitro and in vivo